Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults

Rationale and design of a randomized controlled effectiveness trial

Joshua Lee, Peter D. Friedmann, Tamara Y. Boney, Randall A. Hoskinson, Ryan McDonald, Michael Gordon, Marc Fishman, Donna T. Chen, Richard J. Bonnie, Timothy W. Kinlock, Edward V. Nunes, James W. Cornish, Charles P. O'Brien

Research output: Contribution to journalArticle

Abstract

Background: Extended-release naltrexone (XR-NTX, Vivitrol® Alkermes Inc.) is an injectable monthly sustained-release mu opioid receptor antagonist. XR-NTX is a potentially effective intervention for opioid use disorders and as relapse prevention among criminal justice system (CJS) populations. Methods: This 5-site open-label randomized controlled effectiveness trial examines whether XR-NTX reduces opioid relapse compared with treatment as usual (TAU) among community dwelling, non-incarcerated volunteers with current or recent CJS involvement. The XR-NTX arm receives 6 monthly XR-NTX injections at Medical Management visits; the TAU group receives referrals to available community treatment options. Assessments occur every 2. weeks during a 24-week treatment phase and at 12- and 18-month follow-ups. The primary outcome is a relapse event, defined as either self-report or urine toxicology evidence of ≥. 10. days of opioid use in a 28-day (4. week) period, with a positive or missing urine test counted as 5. days of opioid use. Results: We describe the rationale, specific aims, and design of the study. Alternative design considerations and extensive secondary aims and outcomes are discussed. Conclusions: XR-NTX is a potentially important treatment and relapse prevention option among persons with opioid dependence and CJS involvement.ClinicalTrials.gov: NCT00781898.

Original languageEnglish (US)
Pages (from-to)110-117
Number of pages8
JournalContemporary Clinical Trials
Volume41
DOIs
StatePublished - Mar 1 2015

Fingerprint

Naltrexone
Criminal Law
Opioid Analgesics
Randomized Controlled Trials
Recurrence
Secondary Prevention
Urine
Independent Living
Therapeutics
Injections
Narcotic Antagonists
mu Opioid Receptor
Toxicology
Self Report
Volunteers
Referral and Consultation
Population

Keywords

  • Criminal justice
  • Extended-release naltrexone
  • Naltrexone
  • Opioid relapse prevention

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults : Rationale and design of a randomized controlled effectiveness trial. / Lee, Joshua; Friedmann, Peter D.; Boney, Tamara Y.; Hoskinson, Randall A.; McDonald, Ryan; Gordon, Michael; Fishman, Marc; Chen, Donna T.; Bonnie, Richard J.; Kinlock, Timothy W.; Nunes, Edward V.; Cornish, James W.; O'Brien, Charles P.

In: Contemporary Clinical Trials, Vol. 41, 01.03.2015, p. 110-117.

Research output: Contribution to journalArticle

Lee, J, Friedmann, PD, Boney, TY, Hoskinson, RA, McDonald, R, Gordon, M, Fishman, M, Chen, DT, Bonnie, RJ, Kinlock, TW, Nunes, EV, Cornish, JW & O'Brien, CP 2015, 'Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: Rationale and design of a randomized controlled effectiveness trial', Contemporary Clinical Trials, vol. 41, pp. 110-117. https://doi.org/10.1016/j.cct.2015.01.005
Lee, Joshua ; Friedmann, Peter D. ; Boney, Tamara Y. ; Hoskinson, Randall A. ; McDonald, Ryan ; Gordon, Michael ; Fishman, Marc ; Chen, Donna T. ; Bonnie, Richard J. ; Kinlock, Timothy W. ; Nunes, Edward V. ; Cornish, James W. ; O'Brien, Charles P. / Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults : Rationale and design of a randomized controlled effectiveness trial. In: Contemporary Clinical Trials. 2015 ; Vol. 41. pp. 110-117.
@article{364ea9ada6d04aaeaeab3e4532cc7438,
title = "Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: Rationale and design of a randomized controlled effectiveness trial",
abstract = "Background: Extended-release naltrexone (XR-NTX, Vivitrol{\circledR} Alkermes Inc.) is an injectable monthly sustained-release mu opioid receptor antagonist. XR-NTX is a potentially effective intervention for opioid use disorders and as relapse prevention among criminal justice system (CJS) populations. Methods: This 5-site open-label randomized controlled effectiveness trial examines whether XR-NTX reduces opioid relapse compared with treatment as usual (TAU) among community dwelling, non-incarcerated volunteers with current or recent CJS involvement. The XR-NTX arm receives 6 monthly XR-NTX injections at Medical Management visits; the TAU group receives referrals to available community treatment options. Assessments occur every 2. weeks during a 24-week treatment phase and at 12- and 18-month follow-ups. The primary outcome is a relapse event, defined as either self-report or urine toxicology evidence of ≥. 10. days of opioid use in a 28-day (4. week) period, with a positive or missing urine test counted as 5. days of opioid use. Results: We describe the rationale, specific aims, and design of the study. Alternative design considerations and extensive secondary aims and outcomes are discussed. Conclusions: XR-NTX is a potentially important treatment and relapse prevention option among persons with opioid dependence and CJS involvement.ClinicalTrials.gov: NCT00781898.",
keywords = "Criminal justice, Extended-release naltrexone, Naltrexone, Opioid relapse prevention",
author = "Joshua Lee and Friedmann, {Peter D.} and Boney, {Tamara Y.} and Hoskinson, {Randall A.} and Ryan McDonald and Michael Gordon and Marc Fishman and Chen, {Donna T.} and Bonnie, {Richard J.} and Kinlock, {Timothy W.} and Nunes, {Edward V.} and Cornish, {James W.} and O'Brien, {Charles P.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.cct.2015.01.005",
language = "English (US)",
volume = "41",
pages = "110--117",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults

T2 - Rationale and design of a randomized controlled effectiveness trial

AU - Lee, Joshua

AU - Friedmann, Peter D.

AU - Boney, Tamara Y.

AU - Hoskinson, Randall A.

AU - McDonald, Ryan

AU - Gordon, Michael

AU - Fishman, Marc

AU - Chen, Donna T.

AU - Bonnie, Richard J.

AU - Kinlock, Timothy W.

AU - Nunes, Edward V.

AU - Cornish, James W.

AU - O'Brien, Charles P.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background: Extended-release naltrexone (XR-NTX, Vivitrol® Alkermes Inc.) is an injectable monthly sustained-release mu opioid receptor antagonist. XR-NTX is a potentially effective intervention for opioid use disorders and as relapse prevention among criminal justice system (CJS) populations. Methods: This 5-site open-label randomized controlled effectiveness trial examines whether XR-NTX reduces opioid relapse compared with treatment as usual (TAU) among community dwelling, non-incarcerated volunteers with current or recent CJS involvement. The XR-NTX arm receives 6 monthly XR-NTX injections at Medical Management visits; the TAU group receives referrals to available community treatment options. Assessments occur every 2. weeks during a 24-week treatment phase and at 12- and 18-month follow-ups. The primary outcome is a relapse event, defined as either self-report or urine toxicology evidence of ≥. 10. days of opioid use in a 28-day (4. week) period, with a positive or missing urine test counted as 5. days of opioid use. Results: We describe the rationale, specific aims, and design of the study. Alternative design considerations and extensive secondary aims and outcomes are discussed. Conclusions: XR-NTX is a potentially important treatment and relapse prevention option among persons with opioid dependence and CJS involvement.ClinicalTrials.gov: NCT00781898.

AB - Background: Extended-release naltrexone (XR-NTX, Vivitrol® Alkermes Inc.) is an injectable monthly sustained-release mu opioid receptor antagonist. XR-NTX is a potentially effective intervention for opioid use disorders and as relapse prevention among criminal justice system (CJS) populations. Methods: This 5-site open-label randomized controlled effectiveness trial examines whether XR-NTX reduces opioid relapse compared with treatment as usual (TAU) among community dwelling, non-incarcerated volunteers with current or recent CJS involvement. The XR-NTX arm receives 6 monthly XR-NTX injections at Medical Management visits; the TAU group receives referrals to available community treatment options. Assessments occur every 2. weeks during a 24-week treatment phase and at 12- and 18-month follow-ups. The primary outcome is a relapse event, defined as either self-report or urine toxicology evidence of ≥. 10. days of opioid use in a 28-day (4. week) period, with a positive or missing urine test counted as 5. days of opioid use. Results: We describe the rationale, specific aims, and design of the study. Alternative design considerations and extensive secondary aims and outcomes are discussed. Conclusions: XR-NTX is a potentially important treatment and relapse prevention option among persons with opioid dependence and CJS involvement.ClinicalTrials.gov: NCT00781898.

KW - Criminal justice

KW - Extended-release naltrexone

KW - Naltrexone

KW - Opioid relapse prevention

UR - http://www.scopus.com/inward/record.url?scp=84921901651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921901651&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2015.01.005

DO - 10.1016/j.cct.2015.01.005

M3 - Article

VL - 41

SP - 110

EP - 117

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

ER -